Upcoming Formulary Changes
June 1, 2023FDA Approves Vevye (cyclosporine) Ophthalmic Solution for the Treatment of the Signs and Symptoms of Dry Eye Disease
June 8, 2023
Effective on 7/1/2023 As your Prescription Benefit Facilitator, BeneCard PBF is committed to providing the highest quality service, innovative clinical solutions, and valuable trend management strategies.
BeneCard PBF controls trend through several factors, including our unique pass-through model, generic maximization, clinical programs, and formulary management. The BeneCard PBF Pharmacy and Therapeutics (P&T) Committee continually reviews the latest information available to keep our clinical rules and programs up to date to improve care and reduce costs.
As a result of detailed discussions regarding each medication, its indications, FDA guidelines, and potential member safety issues, the following changes have been approved.
Additions to the Specialty Medication and Standard Clinical Review List
For your reference, we have included the Therapeutic Category as well as the medication use.
- A glycine-proline-glutamate analog.
- Indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.
- It is administered orally twice daily, morning and evening, according to patient weight. DAYBUE can be given with or without food.
- There are warnings for diarrhea and weight loss.
- An endothelin and angiotensin II receptor antagonist.
- Indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.
- It is administered orally at 200 mg orally once daily. After 14 days, increase to the recommended dose of 400 mg once daily, as tolerated.
- It is contraindicated in patients who are pregnant, or when coadministered with angiotensin receptor blockers, endothelin receptor antagonists, or aliskiren.
- There are black box warnings for hepatotoxicity and embryo-fetal toxicity.
- There are additional warnings for Filspari REMS, hypotension, acute kidney injury, hyperkalemia, and fluid retention.
- A kinase inhibitor.
- Indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older and weighing at least 45kg.
- It is administered orally twice daily approximately 12 hours apart, with or without food.
- There are warnings for embryo- fetal toxicity and vaccinations.